title: [Efficacy of antioxidant energocorreсtion in brain infarction (results of a multicenter randomized trial)].
abstract: OBJECTIVE
  To determine the optimal duration of energy corrective treatment of ischemic stroke (II) with cytoflavin or ascorbic acid.
  
  
  METHODS
  A multicenter randomized clinical trial included 185 patients, aged 40-75 years. Patients were randomized into 3 groups: the control group (n=64) received ascorbic acid; cytoflavin group 1 (n=72) was treated for 10 days and cytoflavin group 2 (n=49) for 20 days. In all groups, mean NIHSS score was 13, 42.2% of patients scored ≥14 and on admission, 42.2% of patients had consciousness impairment of different severity.
  
  
  RESULTS
  Cytoflavin treatment was more efficient than ascorbic acid that can be explained by different pharmacologic mechanisms. Treatment with cytoflavin for 10 days resulted in a significant decrease of ischemia zone volume by 25.2%, treatment with cytoflavin for 20 days - by 29.0%, which was associated with better outcomes in neurologic and functional status. Ascorbic acid demonstrated no effect on morphologic parameters. Prolonged treatment with cytoflavin in critically ill patients led to significant improvement in clinical and morphologic variables compared to the 10-day course. In patients with less severe condition comparable results were obtained.
  
  
  CONCLUSIONS
  Our data justify the need for personalized integrated antioxidant and energy correction therapy.
authors.forename: S A
authors.initials: SA
authors.lastname: Rumyantseva
authors.forename: E V
authors.initials: EV
authors.lastname: Silina
authors.forename: L V
authors.initials: LV
authors.lastname: Chichanovskaya
authors.forename: M V
authors.initials: MV
authors.lastname: Nazarov
authors.forename: L A
authors.initials: LA
authors.lastname: Tsukurova
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: E N
authors.initials: EN
authors.lastname: Kabaeva
authors.forename: V A
authors.initials: VA
authors.lastname: Stupin
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D020520:Brain Infarction / Q000188:drug therapy*; D002545:Brain Ischemia / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000627:therapeutic use*; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D001205:Ascorbic Acid